Replies to post #382201 on NorthWest Biotherapeutics Inc (NWBO)

[Kaizenman]

hyperopia: Great find!

Any guesses on how long it would take to show safety and effectivity for blood cancers vs, solid cancers? Could their study last a decade or could it be done sooner than for DCVax-L? Just wondering. Peace.

[Caligoldenbear11]

It's very interesting they are using DCs for blood cancers. This sounds like DCVax-Direct in a combo trial with the checkpoint inhibitors that LP talked about a while ago. Good to know the trial is not sponsored by another company...

[flipper44]

Very interesting. Thanks. I’ll try to find out a little more.

[flipper44]

It might be helpful to know that NWBO does assign DCVax to institutions like NIH — apparently to study it separately or in tandem.

[biosectinvestor]

Notably at this time the only sponsor is Mayo Clinic in collaboration with the NCI.


There are other interesting DC related trials, some of the more interesting also without major corporate involvement. Once NWBO is properly capitalized, they can and probably should consider possible collaborations with some of these independent researchers.

[Doc logic]

hyperopia,

What is interesting in the observations about PDL-1 expression on DCs in this article is that Dr. Prins years ago stated that they thought that the interference from checkpoint response was coming mainly from DCs and it turned out to be primarily from macrophages. This tells me that there is a difference between DCVax-L and Direct activation that can be identified by another activated state comparison, ie this study, which is in line with the Direct patent that points to an optimized maturation state and optimized amount of activation factor to produce DCs that produce a specific signaling pattern. Once that is done then just making sure that signaling remains constant by refreshing the signaling at the right interval will keep checkpoint interference from happening until the tumor has been completely destroyed.

The hit or miss kind of partial response in this study seems to be pointing to generic DCs and there is improper spacing of treatments based on how Direct will be administered in all future trials. There is no way, just based on casual observation, that this is Direct because I do not believe NWBO would allow it to be utilized this way when NWBO knows how it ought to be utilized for best effect. Best wishes.

[GoodGuyBill]

The NIH is an assignee of the DCVAX combo-patent.

2016-12-20 AS Assignment
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA LOS ANGELES;REEL/FRAME:040697/0177

Effective date: 20161216

[jondoeuk]

The sponsor is the Mayo Clinic and the NCI is a collaborator. So the only thing MRK is doing is providing Keytruda.